Introduction to the NETHERTON NOW Video Series
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has taken an enlightening step by releasing its fifth episode of the NETHERTON NOW video series. This special installment highlights the moving stories of twin sisters, Allie and Kaleigh Fasanella, both of whom live with Netherton Syndrome. Through their candid conversation, they share the lifelong challenges and emotional costs associated with this rare skin condition.
Individual Journeys with Netherton Syndrome
Diagnosed in their infancy, Allie and Kaleigh reveal how Netherton Syndrome has profoundly affected their daily lives. This rare genetic skin disorder leads to painful flare-ups and affects mental well-being, making even simple tasks burdensome. They express how the unpredictability of their condition impacts their routines and social interactions, including schooling and attending events like weddings.
Emotional Impact and Mental Health
During the video, Allie candidly shares, “Having Netherton has affected my mental health profoundly.” She elaborates on the relentless cycle of discomfort that complicates everyday life. Kaleigh adds an important perspective, expressing how the emotional turbulence often leads to feelings of depression and isolation. She advises fellow patients to practice self-compassion and treasure small moments of joy.
A Shared Passion for Storytelling
Despite the hardships posed by their condition, both sisters have carved out successful careers in digital media. Kaleigh works as a freelance writer and editor for prominent publications like Allure and Teen Vogue. Allie, too, has made a name for herself with bylines in platforms like Cosmopolitan and NYLON, focusing on beauty and fashion. Their professional backgrounds in storytelling offer them a unique platform to express the intricacies of living with Netherton Syndrome.
Building Identity Beyond the Syndrome
“It’s such a huge part of our identities at this point,” Kaleigh remarks, emphasizing the importance of support systems. As they navigate the complexities of their condition, the sisters exemplify resilience, focusing on personal growth and connection. Their journey signifies that pain does not define identity.
Quoin Pharmaceuticals' Commitment
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, highlights the significance of sharing personal stories like those of Allie and Kaleigh. By amplifying voices of patients, Quoin aims to increase understanding of the challenges faced by individuals with Netherton Syndrome. Quoin's ongoing efforts to raise awareness are reinforced through the NETHERTON NOW campaign, which seeks to shed light on various aspects of living with this condition.
Advancements in Treatment
As part of its mission, Quoin is actively advancing QRX003, its lead product candidate, into pivotal clinical trials. Preliminary results have been promising, showcasing significant improvements in patients’ clinical outcomes. Quoin’s dedication to developing effective therapies emphasizes its role in addressing the needs of those affected by Netherton Syndrome.
The Future of Netherton Syndrome Awareness
Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals, shares that the NETHERTON NOW initiative has garnered positive responses since its inception. The goal remains clear: to further awareness of Netherton Syndrome and work toward bringing forward the first approved therapy.
Conclusion
In sum, the fifth video of the NETHERTON NOW series illustrates not just the struggles faced by those living with Netherton Syndrome, but also the strength they possess. By telling their story and sharing their battles, Allie and Kaleigh empower the community, helping others to feel less alone in their journeys. Their experiences serve as vital reminders of the importance of kindness, resilience, and the shared experiences that connect us all.
Frequently Asked Questions
What is Netherton Syndrome?
Netherton Syndrome is a rare genetic skin disorder characterized by a range of symptoms including skin lesions, hair shedding, and potential allergies.
Who are Allie and Kaleigh Fasanella?
Allie and Kaleigh Fasanella are twin sisters who live with Netherton Syndrome and share their experiences through Quoin Pharmaceuticals' video series.
What is the purpose of the NETHERTON NOW video series?
The series aims to raise awareness about Netherton Syndrome and highlight the everyday challenges faced by those living with the disease.
What is QRX003?
QRX003 is Quoin Pharmaceuticals' lead product candidate, currently in clinical trials, aimed at treating Netherton Syndrome.
How can I support Netherton Syndrome awareness?
You can support awareness efforts by sharing information, learning more about the condition, and participating in campaigns that promote understanding.
